What is the current stock price of Inhibrx Biosciences, Inc. (INBX)?

As of the latest market data, Inhibrx Biosciences, Inc. (INBX) is trading at $103.00. The stock has seen a loss of -3.60% today.

Does Inhibrx Biosciences, Inc. (INBX) pay a dividend?

Based on current data, Inhibrx Biosciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Inhibrx Biosciences, Inc.?

The current market capitalization of Inhibrx Biosciences, Inc. (INBX) is approximately unavailable.

INBX

Inhibrx Biosciences, Inc.·Healthcare

103.00

3.603%(−3.85)

Close Price

112.00

8.738%(+9.00)

After Hours

Last Updated: — ET

52W L: $12.7252W H: $155.29

INBX NEWS

prnewswire.com

May 14

Inhibrx Reports First Quarter 2026 Financial Results

SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.

benzinga.com

May 11

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are trading higher on Monday as the company is reporting positive interim results from its Phase 2 study of INBRX-106 in combination with Merck & Co. Inc.'s (NYSE:MRK) Keytruda (pembrolizumab) for treating head and neck cancer.

marketbeat.com

May 11

Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences NASDAQ: INBX reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and deeper tumor reductions versus KEYTRUDA alone.

prnewswire.com

May 11

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR. Superior depth of response: Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceeding 50%; notably, three patients achieved a complete radiographic response.

prnewswire.com

May 8

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT – SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Monday, May 11, 2026 at 5:30 a.m.

zacks.com

Apr 23

INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study

Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Sector

Healthcare

Industry

Biotechnology

Employees

156

IPO Date

2024-06-04

Beta

3.89

Websiteinhibrx.com↗